Company Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases.
Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease.
The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection.
The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023.
Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
| Country | United Kingdom |
| Founded | 2016 |
| IPO Date | Apr 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 105 |
| CEO | William Enright |
Contact Details
Address: Zeus Building, Unit 6-10 Didcot, OX11 0DF United Kingdom | |
| Phone | 44 1865 818 808 |
| Website | barinthusbio.com |
Stock Details
| Ticker Symbol | BRNS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001828185 |
| CUSIP Number | 91864C107 |
| ISIN Number | US91864C1071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William J. Enright MBA | Chief Executive Officer, Director and Principal Financial Officer |
| Graham Griffiths | Chief Operating Officer |
| Gemma Brown | Principal Accounting Officer |
| Sarah Gilbert | Co-Founder |
| Dr. Geoffrey Lynn M.D., Ph.D. | Chief Scientific Officer |
| Dr. Leon Hooftman M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2025 | 8-K | Current Report |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |